SEARCH

SEARCH BY CITATION

References

  • 1
    Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853860.
  • 2
    Wit FW, Van Leeuwen R, Weverling GJ et al. Outcome and predictors of failure of highly active antiretroviral therapy: one year follow-up of a cohort of human immunodeficiency type-1-infected persons. J Infect Dis 1999; 179: 790798.
  • 3
    Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35F43.
  • 4
    Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 2130.
  • 5
    Nieuwkerk PT, Sprangers MA, Burger DM et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161: 19621968.
  • 6
    Tseng AL. Compliance issues in the treatment of HIV infection. Am J Health Syst Pharm 1998; 55: 18171824.
  • 7
    Stone VE, Hogan JW, Schuman P et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: a survey of women in the HER study. J Acquir Immune Def Syndr 2001; 28: 124131.
  • 8
    Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001; 33: 865872.
  • 9
    Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275291.
  • 10
    Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46: 746754.
  • 11
    Burger DM, Hugen PWH, Van Der Ende ME et al. Once-daily indinavir plus ritonavir: preliminary results of the PIPO study. AIDS 2000; 14: 26212623.
  • 12
    Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV-infection. J Acquir Immune Defic Syndr 2001; 27: 260265.
  • 13
    Heeswijk van RPG, Veldkamp AI, Mulder JW et al. Once daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals. A pharmacokinetic pilot study. AIDS 2000; 14: F95F99.
  • 14
    Kilby JM, Sfakianos G, Gizzi N et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44: 26722678.
  • 15
    Cardiello PG, Van Heeswijk RP, Hassink EA et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002; 29: 464470.
  • 16
    Bardsley-Elliott A, Plosker GL. Nelfinavir, an update of its use in HIV infection. Drugs 2000; 59: 581620.
  • 17
    Sandoval TM, Grettenberger HM, Zhang KE et al. Metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor, by human liver microsomes and recombinant human isoforms [Abstract 1096]. 12th Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists. San Francisco: , November 1998.
  • 18
    Lillibridge JH, Lee CA, Pithavala YK et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate. 12th Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists. San Francisco: , November 1998[Abstract 3035].
  • 19
    Baede-van Dijk PA, Hugen PWH, Verweij-van Wissen CPWGM et al. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15: 991998.
  • 20
    Zhang KE, Wu E, Patick AK et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45: 10861093.
  • 21
    Flexner C. Steady–state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV) and the nelfinavir active metabolite M8 (AG1402). 12th World AIDS Conference, Geneva, 28 June to 3 July, 1998[Abstract 42265].
  • 22
    Kurowski M, Kaeser B, Sawyer A et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther 2002; 72: 123132.
  • 23
    Reijers MH, Weigel HM, Hart AA et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000; 14: 5967.
  • 24
    Hsyu P, Flexner C, Chu A et al. Correlation of efficacy, nelfinavir pharmacokinetics, and diarrhea in treatment-naive HIV positive patients receiving nelfinavir, zidovudine and lamivudine. 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk: April 24, 2001[Abstract 4.4].
  • 25
    Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345356.
  • 26
    Hugen PWH, Verweij-van Wissen CPWGM, Burger DM et al. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir by reversed-phase high-performance liquid chromatography. J Chrom B Biomed Sci Appl 1999; 727: 139149.
  • 27
    Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics, Ed GibaldiM. Philadelphia and London: Lea and Febiger, 1991: 1423.
  • 28
    US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies: Study Design, Data Analysis, and Labeling (Draft Guidance) URL: http:www.fda.gov, accessed 2002, July 3.
  • 29
    Viraceptâ Product Monograph. Basel: Hoffmann-La Roche Ltd,
  • 30
    Burger DM, Hugen PWH, Aarnoutse RE et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. AIDS 2000; 14 (S4): 258.
  • 31
    Pellegrin I, Breilh D, Montestruc F et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16: 13311340.
  • 32
    Hsyu PH, Lewis RH, Tran JQ et al. Pharmacokinetics (PK) of nelfinavir (NFV) after once daily dosing in combination with mini-doses of ritonavir (RTV) in healthy volunteers. XIII International AIDS Conference, Durban: July 914, 2000.
  • 33
    Acosta EP, Kakuda TN, Brundage RC et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30 (Suppl. 2): S151S159.
  • 34
    Johnson M, Petersen A, Johnson M et al. Comparison of BID and TID dosing of Viracept (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago: February 1998[Abstract 373].